Healthcare provider profile · identity verified

Ruben Cabral, MD

Allopathic & Osteopathic Physicians|Internal Medicine · FULLERTON, CA · NPI 1568458008

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Ruben Cabral, MD received $48.58 in general payments during 2025 across 2 reported records.

Novo Nordisk Inc accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 2 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.

Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 284 claims for Ozempic by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$48.58

2 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Novo Nordisk Inc	Unresolved — no canonical attribution shown	$48.58	100.0%	2	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$48.58	2

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
Ozempic Normalized: ozempic	Drug	Novo Nordisk Inc	$48.58	2	2025
Source payment records 2025-01-25 · Novo Nordisk Inc · $25.48 · Open Payments source 2025-08-01 · Novo Nordisk Inc · $23.10 · Open Payments source
Rybelsus Normalized: rybelsus	Drug	Novo Nordisk Inc	$25.48	1	2025
Source payment records 2025-01-25 · Novo Nordisk Inc · $25.48 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
Ozempic ozempic	2025	Ozempic	2024	284	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Novo Nordisk Inc Exact reporting entity; no affiliate inference	2025	Ozempic open payments reported associated product	CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076	Ozempic · 2024 Exact normalized brand match · 1 Part D row	284	49

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	1649	458
Losartan Potassium	Losartan Potassium	992	280
Amlodipine Besylate	Amlodipine Besylate	913	259
Levothyroxine Sodium	Levothyroxine Sodium	656	172
Omeprazole	Omeprazole	605	183
Gabapentin	Gabapentin	586	192
Duloxetine Hcl	Duloxetine Hcl	526	149
Metformin Hcl	Metformin Hcl	487	148
Eliquis	Apixaban	382	81
Pantoprazole Sodium	Pantoprazole Sodium	329	90
Lisinopril	Lisinopril	323	84
Rosuvastatin Calcium	Rosuvastatin Calcium	314	103
Alendronate Sodium	Alendronate Sodium	313	101
Metoprolol Succinate	Metoprolol Succinate	306	84
Escitalopram Oxalate	Escitalopram Oxalate	300	76
Ozempic	Semaglutide	284	49
Potassium Chloride	Potassium Chloride	257	81
Simvastatin	Simvastatin	248	76
Zolpidem Tartrate	Zolpidem Tartrate	227	47
Carvedilol	Carvedilol	204	55
Tamsulosin Hcl	Tamsulosin Hcl	204	65
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	199	49
Trulicity	Dulaglutide	178	36
Jardiance	Empagliflozin	177	44
Donepezil Hcl	Donepezil Hcl	174	48
Sertraline Hcl	Sertraline Hcl	171	47
Azithromycin	Azithromycin	165	131
Spironolactone	Spironolactone	164	49
Lorazepam	Lorazepam	163	41
Furosemide	Furosemide	153	57
Memantine Hcl	Memantine Hcl	148	26
Alprazolam	Alprazolam	145	52
Albuterol Sulfate Hfa	Albuterol Sulfate	141	59
Mirtazapine	Mirtazapine	141	45
Allopurinol	Allopurinol	130	39
Atenolol	Atenolol	130	33
Metoprolol Tartrate	Metoprolol Tartrate	129	41
Hydrochlorothiazide	Hydrochlorothiazide	118	41
Pregabalin	Pregabalin	116	38
Prednisone	Prednisone	112	67
Quetiapine Fumarate	Quetiapine Fumarate	112	25
Famotidine	Famotidine	104	34
Valsartan	Valsartan	102	30
Januvia	Sitagliptin Phosphate	101	22
Celecoxib	Celecoxib	99	24
Finasteride	Finasteride	95	34
Metformin Hcl Er	Metformin Hcl	95	34
Mounjaro	Tirzepatide	95	18
Wixela Inhub	Fluticasone Propion/Salmeterol	93	33
Chlorthalidone	Chlorthalidone	92	31
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	92	30
Clonazepam	Clonazepam	90	16
Synthroid	Levothyroxine Sodium	89	27
Xarelto	Rivaroxaban	84	18
Pioglitazone Hcl	Pioglitazone Hcl	83	26
Fluticasone Propionate	Fluticasone Propionate	82	34
Montelukast Sodium	Montelukast Sodium	81	29
Tramadol Hcl	Tramadol Hcl	81	23
Estradiol	Estradiol	80	28
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	79	25
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	77	56
Trazodone Hcl	Trazodone Hcl	77	25
Benazepril Hcl	Benazepril Hcl	76	24
Hydralazine Hcl	Hydralazine Hcl	75	17
Ibuprofen	Ibuprofen	74	27
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	72	26
Ciprofloxacin Hcl	Ciprofloxacin Hcl	71	50
Warfarin Sodium	Warfarin Sodium	71	18
Ondansetron Odt	Ondansetron	68	33
Fluocinonide	Fluocinonide	67	50
Citalopram Hbr	Citalopram Hydrobromide	66	15
Clopidogrel	Clopidogrel Bisulfate	66	20
Temazepam	Temazepam	64	16
Triamcinolone Acetonide	Triamcinolone Acetonide	64	41
Glipizide	Glipizide	63	21
Labetalol Hcl	Labetalol Hcl	63	13
Myrbetriq	Mirabegron	58	suppressed
Valacyclovir	Valacyclovir Hcl	58	23
Torsemide	Torsemide	57	17
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	56	19
Ezetimibe	Ezetimibe	56	15
Klor-Con 10	Potassium Chloride	56	21
Fluoxetine Hcl	Fluoxetine Hcl	55	15
Venlafaxine Hcl Er	Venlafaxine Hcl	54	15
Glimepiride	Glimepiride	52	13
Meclizine Hcl	Meclizine Hcl	52	12
Paxlovid	Nirmatrelvir/Ritonavir	52	52
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	50	11
Lovastatin	Lovastatin	49	12
Pravastatin Sodium	Pravastatin Sodium	49	17
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	48	12
Sumatriptan Succinate	Sumatriptan Succinate	47	15
Cephalexin	Cephalexin	45	33
Breo Ellipta	Fluticasone/Vilanterol	44	12
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	44	13
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	42	21
Hydrocortisone	Hydrocortisone	42	15
Bupropion Xl	Bupropion Hcl	41	11
Linzess	Linaclotide	41	suppressed
Terazosin Hcl	Terazosin Hcl	41	12
Digoxin	Digoxin	40	12
Olmesartan Medoxomil	Olmesartan Medoxomil	40	suppressed
Ipratropium Bromide	Ipratropium Bromide	39	16
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	38	13
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	38	suppressed
Diclofenac Sodium	Diclofenac Sodium	35	13
Premarin	Estrogens, Conjugated	35	suppressed
Sildenafil Citrate	Sildenafil Citrate	35	suppressed
Colchicine	Colchicine	33	14
Fluconazole	Fluconazole	33	21
Isosorbide Mononitrate Er	Isosorbide Mononitrate	33	suppressed
Azelastine Hcl	Azelastine Hcl	30	11
Bupropion Hcl Sr	Bupropion Hcl	30	suppressed
Potassium Citrate Er	Potassium Citrate	30	suppressed
Buspirone Hcl	Buspirone Hcl	29	suppressed
Meloxicam	Meloxicam	29	13
Nitroglycerin	Nitroglycerin	29	15
Amitriptyline Hcl	Amitriptyline Hcl	28	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	28	suppressed
Diazepam	Diazepam	27	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	27	11
Glipizide Er	Glipizide	27	suppressed
Lansoprazole	Lansoprazole	27	suppressed
Paroxetine Hcl	Paroxetine Hcl	27	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	26	15
Propranolol Hcl	Propranolol Hcl	26	suppressed
Ibandronate Sodium	Ibandronate Sodium	25	suppressed
Creon	Lipase/Protease/Amylase	24	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	23	13
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	23	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	23	suppressed
Divalproex Sodium	Divalproex Sodium	23	suppressed
Entresto	Sacubitril/Valsartan	23	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	23	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	22	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	22	suppressed
Testosterone	Testosterone	22	suppressed
Clomipramine Hcl	Clomipramine Hcl	21	suppressed
Alcohol Pads	Alcohol Antiseptic Pads	20	suppressed
Lactulose	Lactulose	20	suppressed
Ondansetron Hcl	Ondansetron Hcl	20	suppressed
Rizatriptan	Rizatriptan Benzoate	20	suppressed
Ezetimibe-Simvastatin	Ezetimibe/Simvastatin	19	suppressed
Fenofibrate	Fenofibrate,micronized	19	suppressed
Humalog Kwikpen U-200	Insulin Lispro	19	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	19	suppressed
Midodrine Hcl	Midodrine Hcl	19	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	19	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	19	suppressed
Solifenacin Succinate	Solifenacin Succinate	19	suppressed
Amlodipine-Valsartan	Amlodipine Besylate/Valsartan	18	suppressed
Methylprednisolone	Methylprednisolone	18	18
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	18	15
Breyna	Budesonide/Formoterol Fumarate	17	suppressed
Cefuroxime	Cefuroxime Axetil	17	12
Clobetasol Propionate	Clobetasol Propionate	17	suppressed
Levetiracetam	Levetiracetam	17	suppressed
Lubiprostone	Lubiprostone	17	suppressed
Nadolol	Nadolol	17	suppressed
Naproxen	Naproxen	17	suppressed
Ventolin Hfa	Albuterol Sulfate	17	suppressed
Verapamil Er	Verapamil Hcl	17	suppressed
Candesartan Cilexetil	Candesartan Cilexetil	16	suppressed
Clonidine	Clonidine	16	suppressed
Cyanocobalamin Injection	Cyanocobalamin (Vitamin B-12)	16	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	16	suppressed
Methimazole	Methimazole	16	suppressed
Olanzapine	Olanzapine	16	suppressed
Ranolazine Er	Ranolazine	16	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	15	suppressed
Mometasone Furoate	Mometasone Furoate	15	suppressed
Varenicline Tartrate	Varenicline Tartrate	15	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	15	suppressed
Amoxicillin	Amoxicillin	14	14
Clonidine Hcl	Clonidine Hcl	14	suppressed
Eszopiclone	Eszopiclone	14	suppressed
Metronidazole	Metronidazole	14	11
Acyclovir	Acyclovir	13	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	13	suppressed
Invokana	Canagliflozin	13	suppressed
Memantine Hcl Er	Memantine Hcl	13	suppressed
Repatha Sureclick	Evolocumab	13	suppressed
Sotalol	Sotalol Hcl	13	suppressed
Topiramate	Topiramate	13	suppressed
Tradjenta	Linagliptin	13	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	12	suppressed
Easy Comfort Pen Needles	Pen Needle, Diabetic	12	suppressed
Enalapril Maleate	Enalapril Maleate	12	suppressed
Haloperidol	Haloperidol	12	suppressed
Ketoconazole	Ketoconazole	12	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Megestrol Acetate	Megestrol Acetate	12	suppressed
Nystatin	Nystatin	12	suppressed
Propafenone Hcl Er	Propafenone Hcl	12	suppressed
Tresiba Flextouch U-100	Insulin Degludec	12	suppressed
Tresiba Flextouch U-200	Insulin Degludec	12	suppressed
Cefdinir	Cefdinir	11	suppressed
Clotrimazole	Clotrimazole	11	suppressed
Erythromycin	Erythromycin Base	11	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	11	suppressed
Janumet Xr	Sitagliptin Phos/Metformin Hcl	11	suppressed
Ketorolac Tromethamine	Ketorolac Tromethamine	11	suppressed
Methenamine Hippurate	Methenamine Hippurate	11	suppressed
Mupirocin	Mupirocin	11	suppressed
Telmisartan	Telmisartan	11	suppressed
Trimethoprim	Trimethoprim	11	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	11	suppressed
Ursodiol	Ursodiol	11	suppressed
Verapamil Sr	Verapamil Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$48.58 · 2 records	Novo Nordisk Inc	Ozempic, Rybelsus	1	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Ozempic play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error